IBDEI05E ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2237,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,2238,0)
 ;;=202.00^^21^189^66
 ;;^UTILITY(U,$J,358.3,2238,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2238,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,2238,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,2238,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,2239,0)
 ;;=200.10^^21^189^65
 ;;^UTILITY(U,$J,358.3,2239,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2239,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,2239,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,2239,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,2240,0)
 ;;=203.00^^21^189^77
 ;;^UTILITY(U,$J,358.3,2240,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2240,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,2240,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,2240,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,2241,0)
 ;;=203.01^^21^189^79
 ;;^UTILITY(U,$J,358.3,2241,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2241,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,2241,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,2241,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,2242,0)
 ;;=V10.21^^21^189^38
 ;;^UTILITY(U,$J,358.3,2242,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2242,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,2242,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,2242,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,2243,0)
 ;;=180.9^^21^189^8
 ;;^UTILITY(U,$J,358.3,2243,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2243,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,2243,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,2243,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,2244,0)
 ;;=203.02^^21^189^78
 ;;^UTILITY(U,$J,358.3,2244,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2244,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,2244,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,2244,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,2245,0)
 ;;=V10.91^^21^189^44
 ;;^UTILITY(U,$J,358.3,2245,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2245,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,2245,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,2245,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,2246,0)
 ;;=196.9^^21^189^62
 ;;^UTILITY(U,$J,358.3,2246,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2246,1,4,0)
 ;;=4^196.9
 ;;^UTILITY(U,$J,358.3,2246,1,5,0)
 ;;=5^Lymph Nodes
 ;;^UTILITY(U,$J,358.3,2246,2)
 ;;=^267313
 ;;^UTILITY(U,$J,358.3,2247,0)
 ;;=204.90^^21^189^63
 ;;^UTILITY(U,$J,358.3,2247,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2247,1,4,0)
 ;;=4^204.90
 ;;^UTILITY(U,$J,358.3,2247,1,5,0)
 ;;=5^Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,2247,2)
 ;;=^336854
 ;;^UTILITY(U,$J,358.3,2248,0)
 ;;=V10.82^^21^189^42
 ;;^UTILITY(U,$J,358.3,2248,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2248,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,2248,1,5,0)
 ;;=5^H/O Malig Melanoma
 ;;^UTILITY(U,$J,358.3,2248,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,2249,0)
 ;;=198.4^^21^189^76
 ;;^UTILITY(U,$J,358.3,2249,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2249,1,4,0)
 ;;=4^198.4
 ;;^UTILITY(U,$J,358.3,2249,1,5,0)
 ;;=5^Mets to Nervous System
 ;;^UTILITY(U,$J,358.3,2249,2)
 ;;=^267335
 ;;^UTILITY(U,$J,358.3,2250,0)
 ;;=202.80^^21^189^80
 ;;^UTILITY(U,$J,358.3,2250,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2250,1,4,0)
 ;;=4^202.80
 ;;^UTILITY(U,$J,358.3,2250,1,5,0)
 ;;=5^Non-Hodgkin's Lymphoma
 ;;^UTILITY(U,$J,358.3,2250,2)
 ;;=^87701
 ;;^UTILITY(U,$J,358.3,2251,0)
 ;;=V10.02^^21^189^53
 ;;^UTILITY(U,$J,358.3,2251,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2251,1,4,0)
 ;;=4^V10.02
 ;;^UTILITY(U,$J,358.3,2251,1,5,0)
 ;;=5^H/O of Malig Oral/Pharynx
